Physician profile
Daniel Lama
NPI 1235634676
$1,125.13
in general payments reported to CMS, 2019-2025
15 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $269 · 2023: $358 · 2024: $84.81 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $217.66 | 2021-2023 | Spaceoar Vue System - 10ml |
| Myovant Sciences INC. | $191.64 | 2021-2022 | |
| Urogen Pharma, INC. | $157.22 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $95.15 | 2023 | Pylarify |
| Medtronic, INC. | $85.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.54 | 2023 | |
| Davol INC. | $52.04 | 2025 | Phasix Mesh |
| Olympus America INC. | $44.96 | 2025 | Shockpulse, Soltive |
| Astellas Pharma US INC | $39.82 | 2022 | |
| Convatec INC. | $38.13 | 2023 | |
| Intuitive Surgical, INC. | $37.38 | 2024 | |
| Immunitybio, INC. | $33.34 | 2025 | |
| Janssen Biotech, INC. | $27.22 | 2025 | Erleada |
| Merck Sharp & Dohme LLC | $24.96 | 2024 | Welireg, Keytruda |
| Eisai INC. | $22.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.